Abstract: Pheochromocytomas (PCs) and paragangliomas (PGLs) are routinely localized by computed tomography (CT), magnetic resonance imaging (MRI), and metaiodobenzylguanidine (MIBG) scintigraphy. CT can identify tumors with high sensitivity but rather low specificity. MRI has higher sensitivity and specificity than CT and is superior to detect extra-adrenal disease. Radioiodinated MIBG scintigraphy has been used for more than 30 years and is based on MIBG uptake via the norepinephrine transporter on the cell membrane. The technique is very useful for whole-body studies in case of multiple primary tumors or metastases. Tumors with sole production of dopamine usually cannot be visualized with MIBG and may require positron emission tomographic (PET) studies with 18 F-labeled radiotracers. Somatostatin receptor scintigraphy (SRS) using the radiolabeled somatostatin analog octreotide (based on the expression of the somatostatin receptors 2 and 5 by the tumor) can demonstrate PGL or metastases not visualized by MIBG. In this article, we review the use of MIBG scintigraphy to diagnose PC/PGL and compare the sensitivity and specificity with that of CT and MRI. We also describe the recent SRS and PET techniques and review the latest results of clinical studies by comparing these imaging modalities. Future perspectives of functional imaging modalities for PC/PGL are finally presented.
Introduction
Pheochromocytomas (PCs) and paragangliomas (PGLs) are rare tumors derived from the adrenal medulla or sympathetic/parasympathetic nervous tissue; PC and sympathetic PGL have excess secretion of catecholamines (CAs). About 10% of PCs are malignant, but the prevalence of malignant tumors is higher for PGL (especially for the hereditary forms with mutations of the succinate dehydrogenase B (SDHB) gene). A significant number of so-called benign tumors will overtime develop metastases.
1,2 Today, there is no reliable method that can distinguish benign from malignant tumors other than the presence of metastases. Patients with PC/PGL are, therefore, annually controlled biochemically for CAs and metabolites, and upon positive tests, whole-body imaging is performed using both computed tomography/magnetic resonance imaging (CT/MRI) and functional imaging techniques. 3 Functional imaging (aimed at tumor localization and detection of CA secretion from each individual lesion) can be performed by scintigraphic visualization of a radioiodinated ( 123 I or 131 I) CA analog (metaiodobenzylguanidine, MIBG), which is actively transported into the secreting tumor cells. MIBG scintigraphy has since long had a central role in the detection of PC/sympathetic PGL and metastases. It is also used for planning of radiotherapy using of the injected dose. 4 Recently developed functional positron emission tomography (PET)-CT techniques using specifically tailored CA molecules ([ (FDG) by malignant cells, seem to have the highest sensitivity and specificity to correctly diagnose PC/PGL and metastases. 5 18 F-DOPA/DA PET is available only at few centers worldwide, which implies that MIBG scintigraphy will still remain the primary technique for functional imaging for several years to come.
Imaging techniques are routinely used for diagnosis of the neuroendocrine (NE) tumor types PC/PGL. The location and metastatic spread is of vital importance when evaluating the prognosis and treatment strategies. CT and MRI are sensitive tools in detecting the primary tumor but have restricted specificity. 6 Therefore, functional imaging of the whole body is usually carried out using tumor-specific techniques, for example, uptake of radioiodine-labeled MIBG into the secretory granules of tumor cells. Scintigraphy using 131 I-labeled MIBG has been widely used with some success for about 30 years. Today, there is a trend toward switching from 131 I-MIBG to 123 I-MIBG. Different opinions have also been proposed regarding the usefulness of MIBG scintigraphy when compared to CT and MRI, with different recommendations for separate patient groups.
Many investigators recommend MIBG imaging prior to surgery, especially in patients with large (.5 cm), extra-adrenal, or multiple tumors. After successful surgery, biochemical testing is performed annually, followed by imaging studies when CA hypersecretion is indicated. In our own long-term population-based series of 154 patients with PC/PGL, we showed that only 12 patients had malignant tumors (8 PCs and 4 PGLs); the worst prognosis was found among the 4 patients presenting with distant metastases, while the tumor progression was slow for the 4 patients with locally advanced disease and the 4 patients who developed metastases despite benign appearance at primary surgery. 2 The aim of this article is to summarize the current knowledge about the imaging methods used routinely or proposed for diagnosis of benign and malignant PC and PGL. Focus is directed toward MIBG scintigraphy, and results are discussed and compared with those of CT and MRI. The recent advances in PET techniques are included and compared with MIBG scintigraphy.
Pheochromocytoma/paraganglioma
Aminergic neurons and NE cells share the capacity to synthesize, store, and release biogenic amines. The amines are synthesized from precursor amino acids in the cytoplasm, followed by transport into storage granules by vesicular monoamine transporter molecules (VMATs) at the vesicular membrane. At stimulation, the amines are released from the granules by exocytosis. The two subtypes of VMATs (VMAT 1 and 2) are structurally similar but have different substrate specificity for serotonin, histamine, and CAs and have different tissue distribution. 7 At the outer cell membrane, the norepinephrine transporter (NET) is responsible for the uptake of CA, or its analogs, from the circulation into sympathetic neurons and adrenal medullary cells. 8 PC and sympathetic PGL are NE tumors derived from chromaffin cells of the adrenal medulla and sympathetic paraganglia (located along the sympathetic trunk in the thorax and abdomen and in the Zuckerkandls organ close to the aortic bifurcation). PGL can also be derived from the parasympathetic nervous system (mainly located in the head-neck region). Some nomenclature confusion has existed, that is, the term 'extra-adrenal PC' has been used to describe all PGL, but some authors have used PGL exclusively for parasympathetic PGL in the head-neck region. For the sake of clarity, we use PC for the intra-adrenal tumors and to distinguish between sympathetic (thoracoabdominal) and parasympathetic (head-neck) PGL. PC and sympathetic PGL can secrete CA, usually epinephrine (EPI) and/or norepinephrine, and more seldom DA. Hypersecretion of EPI/norepinephrine can cause hypertension, headache, palpitations, sweating, and anxiety, which can occur attack-wise (hypertensive crises) and lead to cerebrovascular and cardiac accidents. Parasympathetic PGL can cause local symptoms, but are not associated with excess secretion, even if they may express the acetylcholine transporter. 3, 9, 10 The prevalence of PC/PGL is 0.8 per 100,000 per year.
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Since small and benign tumors with slow growth may be asymptomatic, or only cause vague symptoms, they can remain undiagnosed. This is one explanation for the higher prevalence figures seen in autopsy studies. 12 The tumors are equally common in males and females and usually present at mid-life. 13 Hereditary tumors are often diagnosed at younger age and 10% are present in children. 14, 15 Benign PC is usually located in one of the adrenal glands, while hereditary PC can be bilateral and multicentric. 11 The hereditary tumors are part of familial syndromes, such as von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (NF 1), multiple endocrine neoplasia type 2 (MEN 2), and the Carney syndrome. 16, 17 In VHL and NF 1 (incidence, 1:3000 each), the risk of developing PC is low; VHL is commonly associated with clear cell renal carcinoma and central nervous system hemangioblastoma, and NF 1 is associated with a variety of nerve-related tumors. In MEN 2A, a majority of patients will develop medullary thyroid carcinoma, one-half of them PC, and one-quarter hyperparathyroidism. The Carney syndrome is extremely rare (pulmonary hamartoma, gastrointestinal stromal tumor, and PC/sympathetic PGL). The familial PGL syndromes form a relatively new group of disorders with mutations in subunits of the mitochondrial enzyme succinate dehydrogenase (SDH): type 1 relates to benign parasympathetic PGL in the head-neck region with SDHD mutations, 18 type 2 was just recently described (SDH5 mutations), 19 type 3 also relates to benign parasympathetic head-neck PGL (SDHC mutations), 14 and type 4 is associated with sympathetic PGL with high risk for malignancy (SDHB mutations). 20 Fumarate hydratase is another mitochondrial protein of the tricarboxylic acid cycle/respiratory chain, which in mutated form may lead to development of PC/PGL associated with hereditary leiomyomatosis and renal cell cancer. 21 In addition, a fifth SDH protein (SDH 5 or SDH complex assembly factor 2, SDHAF 2) was recently shown to be a PGL-related tumor suppressor gene. 22 Common for these mitochondrial genes is the stabilization of hypoxia inducible factor 1, leading to upregulation of glycolysis, glucose transport, and angiogenesis (Warburg effect). 23 It is, therefore, likely that these tumors can be visualized via the glucose transporter irrespective of malignant transformation.
The majority of PC/PGL are benign. About 10% of all PCs are malignant, but this percentage is higher for abdominal sympathetic PGL (15%-35%) -even higher in the presence of SDHB mutations. 24, 25 Clinical, biochemical, or radiological features cannot distinguish benign from malignant tumors. 3, 13 No single histopathological features of a resected PC/PGL can predict future metastatic disease. Malignancy has, therefore, been defined as presence of metastases at sites where chromaffin tissue should not be present, for example, skeleton, lungs, liver, and lymph nodes. 26 Malignant tumors are usually large with necrotic portions and are locoregionally invasive 27 and may extend into the caval vein, kidney, and liver. 28 The lack of reliable malignancy predictors necessitates lifelong follow-up of PC/PGL patients.
MIBG
MIBG is a norepinephrine analog with iodine at the meta position in the benzoic ring. MIBG was developed at the University of Michigan Medical School in the late 1970s and was initially used for visualization of the adrenal medulla and myocardium. [29] [30] [31] MIBG is taken up from the circulation by adrenergic/sympathomedullary tissues via NET at the cell membrane into the cytoplasm (type I uptake). This uptake is characterized by high affinity, saturability, and dependence of temperature, energy, and sodium. MIBG is then concentrated into intracytoplasmic storage vesicles via another specific uptake mechanism using the adenosine triphosphatase-dependent VMATs. Granularly stored MIBG can then be released by exocytosis. [32] [33] [34] MIBG does not bind to postsynaptic adrenergic receptors and is claimed to be metabolized only to a very low extent. 32, 35, 36 The interaction between the NET and VMAT transporter systems has not been elucidated so far. In pilot studies, high scintigraphic uptake of 123 I-MIBG was found in two malignant PGL with high VMAT expression (500-730 copies of VMAT1 and 1500-1700 copies of VMAT2 per 1000 copies of β-actin). A third malignant PGL had negative imaging and low VMAT expression (330 copies of VMAT1 and 350 copies of VMAT2 per 1000 copies of β-actin). In vitro, the VMAT antagonist reserpine and membrane pump inhibitors inhibited the uptake of 123 I-MIBG into tumor cells equally well. 37 MIBG can be radiolabeled by exchanging the stable iodine ( 127 I) with a radioactive iodine isotope, usually 123 I are given in Table 1 . Using a similar exchange of the iodine atom with 211 At, MABG has been produced and has been tested for therapy experimentally. 39, 40 MIBG is usually administered intravenously and is excreted mainly via the kidneys (about 85%); 45%-60% of the administered activity is excreted during the first 24 h. 32, 41, 42 Other excretion pathways are via the intestines, sweat, saliva, and exhalation. 35 Normal uptake of MIBG is frequently seen in organs and tissues rich in sympathetic innervation, for example, the myocardium, lungs, spleen, liver, cerebellum, urinary bladder, colon, and salivary glands. [42] [43] [44] [45] [46] [47] Uptake of 123 I-MIBG is found in the heart and lungs in about 90% of the patients. 33, 45, 48 Significant uptake in the large intestine can be seen in late imaging in about 15% of the patients when 131 I-MIBG was used. 42, 44 Uptake in bone tissue does not seem to occur. 44 Although MIBG was initially developed for visualization of the adrenal medulla, the normal adrenal medulla was rarely visualized with 131 I-MIBG, and a very faint adrenal uptake was reported in ,7% of the patients. 32, 41, 49, 50 On the other hand, other studies have demonstrated normal adrenal medulla accumulation of 131 I-MIBG in up to 28% of the patients, with increasing visualization rate for higher administered activities. [51] [52] [53] Using 123 I-MIBG, uptake in the normal adrenal was more commonly visualized. Some studies reported visible adrenal medulla in about 30% of the patients, 48 ,54 but even higher frequencies (50%-80%) have been obtained. 49, 50, 55 The different results between the studies are interestingly not dependent of the given amount of 123 I activity.
MIBG scintigraphy Scintigraphic procedures
For scintigraphy, 123 I-or 131 I-MIBG is slowly administered intravenously. According to the European Association of Nuclear Medicine recommendations, the amount of activity injected is 400 MBq of 123 I-MIBG and 40-80 MBq of 131 I-MIBG for adults, while for children, the administered activity should be scaled according to the body weight of the patient. 56 Thyroid blockage is recommended, either by potassium iodide or potassium perchlorate, as an alternative when the patient is allergic to iodine. 41, 56 The patient is recommended to drink fluids after administration and to void frequently in order to reduce the radioiodine activity in the bladder and thus facilitate for detection of lesions in the vicinity of the bladder. 56 In addition, laxatives can be recommended when imaging the abdomen. 41 Scintigraphic imaging with MIBG is performed using a large field-of-view gamma camera, usually equipped with a low-energy (LE) collimator ( 123 I) or a high-energy (HE) collimator ( 131 I) ( Figures 1B and 2B ). Both anterior and posterior planar views should be acquired together with single photon emission computed tomography (SPECT) for 123 I-MIBG. When using the short-lived 123 I, images are usually acquired at both 24 and 48 hours after injection. 55, 56 Although the optimal imaging time has been found to be 18-24 hours after injection with visual assessment, 48 the 48-hour images can still be helpful; visualization of both intrathoracic and intra-abdominal lesions may be improved due to longer residence time of MIBG in PC/PGL than in normal tissues. 48, 56 Late images are better obtained with the long-lived should be obtained at 24, 48, and 72 hours after injection, with the option of even later images. 51, 56 Maximal uptake is usually seen at 24-48 hours after injection. 43 Sensitivity and specificity of MIBG scintigraphy A summary of the sensitivity and specificity of MIBG scintigraphy in various clinical studies is shown in Tables 2 and 3 . The sensitivity of 131 I-MIBG in detecting PC/PGL was 77%-90%, with a specificity of 95%-100% ( Table 2 ). The number of patients varied much in the studies reported. The study with the largest patient group in this review (n = 400) reported a sensitivity and specificity of 87% and 99%, respectively, 57 in line with the other large studies. A sensitivity of 100% was reported in two studies, but it should be noted that these studies were small (,10 patients in each). 58, 59 In some of the studies, values were given separately for subgroups of PC/PGL. If only PGL was considered, the sensitivity was lower (58%-89%, based on four studies). The sensitivity for malignant disease was found to be 77% in one study and 92% in another study. Another study reported a sensitivity of 100% for malignant disease. 60 The reason for this high value is probably that the main metastatic site was the skeleton. In general, the difference in detection rates between studies is probably related to a variable contribution of parasympathetic and sympathetic PGL to a main population of PC. Such subgroups were not defined in older studies. Using 123 I-MIBG scintigraphy, a sensitivity of 88%-96% and a specificity of 96%-100% have been reported (Table 3 ). The highest sensitivity was obtained in a study consisting only of PC patients. 61 The lowest sensitivity was 75%, 62 which may be due to a large proportion of PGL. Some of these patients may have been parasympathetic head and neck PGL with a documented low sensitivity (44%). 61, 63 In a recent prospective, multicenter trial, where masked readers evaluated the images, the overall sensitivity was 81%-88% and specificity was 75%-84% for 123 I-MIBG scintigraphy of primary and metastatic PC/PGL (Table 3) . 64 Recently, SPECT/CT is used more commonly and has the advantage of simultaneous acquisition of both morphological and functional data. Using 123 I-MIBG SPECT/CT, it is possible to obtain a sensitivity and specificity of 100%. 65 SPECT/CT can differentiate between tumor mass and scar tissue with exact anatomical details and can be useful in cases where diagnostic CT shows equivocal results. 66, 67 It is generally assumed that 123 I-MIBG gives better image quality than 131 I-MIBG, especially better signal contrast and image resolution due to lower photon energy and detection efficiency (see below). The drawback is the shorter half-life limiting the possibility with late images when better contrast would be assumed. Several studies have confirmed better detection possibilities (higher sensitivity and specificity and better visualization of the smallest tumors) with 123 I-MIBG scintigraphy. 32, 49, [68] [69] [70] [71] [72] [73] The MIBG uptake in PC/PGL may also be influenced by various drugs. The salivary glands, liver, and spleen are frequently seen in MIBG images. If no uptake is seen in the normal tissues with rich sympathetic innervation, suspicion should be raised whether the patient is taking medications, or drugs, that interfere with MIBG uptake. [42] [43] [44] [45] Examples of such medications are inhibitors of uptake (labetalol and calcium channel blockers) and storage depleters (reserpine, tricyclic antidepressants, and sympathomimetics). 41, 68, 74 In addition, cocaine and antipsychotics may interfere with the MIBG uptake. 33 The detection efficiency for 123 I-MIBG seems to vary due to the type of tumor, for example, lower for malignant PC than for benign ones. It has also been reported that the 123 I uptake in unilateral, intra-adrenal, and sporadic tumors is higher than in bilateral, extra-adrenal, and familial PC.
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This is in concordance with the findings of two other studies using 131 I-MIBG. 57, 76 With the recent knowledge about the variation in genotype between different tumors (VHL, MEN 2, SDHB, SDHC, SDHD, and nonfamilial), it is likely that the imaging performance might differ between these types and also explain some of the diverging results seen in previous studies. 74 The intensity of MIBG uptake in malignant versus benign PC/PGL can be debated. One study showed that the MIBG uptake in the tumor was lower in malignant than in benign ones. 75 In another study, the signal intensity ratio in malignant lesions was significantly higher than in benign ones. 77 One important difference between these two studies is that the latter includes many patients with recurrent PC. Increased awareness in these cases may lead to earlier tumor detection. Early diagnosed recurrent PC also means lower risk of necrosis, that is, high MIBG uptake. It has been found that malignant PC/PGL is larger at the time of detection compared with benign ones; 78 larger tumors have higher probability of necrosis with lower detection efficiency of MIBG. This explanation is also supported by the findings in a study of one patient examined repeatedly with 123 I-MIBG scintigraphy, with whom the results changed from positive to negative, probably due to dedifferentiation during the tumor progression. 62 False-negative results of MIBG scintigraphy may occur due to several reasons. One obvious factor is insufficient uptake of radioiodinated MIBG by the tumor. 49 Many authors agree that there is a positive correlation between size and MIBG signal intensity. 62, 75, 76 Most of these studies use only visual grading of the images. In a quantitative analysis, the concentration of 131 I in PC/PGL given per gram of tumor tissue was in general similar for all tumors (0.03%-0.09% IA/g), with the exception for the largest tumor (0.004%/g). This finding led the authors to hypothesize that larger tumors are less metabolically active and thus have lower uptake of 131 I-MIBG. 31 Other explanations may involve biological changes in the tumor tissue, for example, loss or reduced expression of the NET or VMAT transporters, dedifferentiation of the tumor, or necrosis formation. 27 
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Diagnostic imaging of pheochromocytoma
The reported detection limit for PC, that is, the smallest tumor volume detectable, can vary. One study reported that PC with negative 123 I-MIBG examination (using visual grading) had a median diameter of 2.3 cm, while detected tumors had a median diameter of 5.0 cm. 62 They also reported that all adrenal tumors ,2.4 cm remained undetected. Very little has been reported on extra-adrenal PC metastases with regard to the detection limit. Using 131 I-MIBG, PC and PGL tumors with a diameter ,3 cm were false negative in 17% of the cases, while tumors larger than that only gave falsenegative results in 10% of the cases. 76 They also found that tumors with a volume of ,20 cm 3 were false negative in 36%, while tumors above this limit were only negative in 3% of the cases. For PGL, a detection limit of 1-2 cm in diameter has been reported for 123 I-MIBG. 48 Another study found that PGL with negative 123 I-MIBG examination had a median diameter of 2.8 cm, while positive lesions had a median diameter of 3.5 cm; no significant correlation between tumor size and visual uptake of 123 I-MIBG for PGL was demonstrated. 62 In general, the images are evaluated visually; quantitative evaluation is only done occasionally, mainly for 
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Forssell-Aronsson et al treatment planning prior to 131 I-MIBG therapy. By visual examination of the positive scintigrams, it might be difficult to distinguish between PC, adrenal medullary hyperplasia, and normal physiological uptake. To increase the diagnostic accuracy, a few slightly different grading systems have been proposed. 54, 62, 70, 75 These grading systems have in common that they consist of a 4-point scale based on visual comparison between the signal intensity in the adrenal gland and that in the normal liver (with minor differences in definition of the scores). In one study including both PC and PGL, the correlation between application of a scoring system and postoperative histological findings demonstrated high sensitivity (92%) and specificity (100%); 63 of 67 patients were correctly diagnosed. 70 In general, such grading systems and scores related to the signal intensity in normal tissues should be avoided due to several reasons: 1) the uptake in a normal tissue might vary considerably between different individuals and 2) in planar images, the visual signal from a small/thin potential tumor is strongly dependent both on the size (area) in the image (due to limited image resolution) and on the depth and thickness versus the reference tissue. Quantitative evaluation is, therefore, strongly recommended for planar scintigraphy. In SPECT, the effects of the second above-mentioned limitation are reduced at least for relatively large tumors, but the problem with interindividual variation in normal tissue uptake remains. (Table 1) , which influence the imaging properties (Table 4) . With 123 I-MIBG, a higher sensitivity can be achieved compared with 131 I-MIBG, which has to do with the numerous drawbacks of 131 I when it comes to diagnostic-imaging performance. 35, 50 The photons emitted by 131 I have higher photon energy than optimal photon energy for use in modern gamma cameras, which requires the use of inefficient collimators lowering the contrast and spatial resolution of the image and reducing counting statistics. 35 Furthermore, 131 I has a long half-life of 8 days, which contributes to high-radiation dose together with a large component of β-particles, which restricts the amount of activity that should be administered. However, the long halflife of 131 I allows delayed imaging, which can be of a certain value, since the retention time of 131 I-MIBG in the adrenal medulla is longer than in the surrounding normal tissues. Late imaging with 131 I-MIBG may thus reveal lesions with low uptake not detected when the background activity is high. 35, 49, 80 The importance to acquire the images at optimal time points has been well demonstrated. 51 For patients receiving higher amounts of 131 I-MIBG (40 MBq), three lesions were visible at day 7 only and all but one lesion were better visualized on images taken after 7 days of administration.
Advantages and disadvantages with
With the use of 123 I, better image quality can be achieved in general. The photon energy of 159 keV for 123 I makes it highly suited for modern gamma cameras. The effective dose for 123 I-MIBG is much lower than for 131 I-MIBG, which allows 15 times higher administered activity of 123 I, without increasing the effective dose (Table 5) . 35 The combination of more suitable photon energy and lower effective dose gives an 80-fold increase in useful photon flux, which results in a better ability to detect lesions and a more accurate definition of the lesion. 35, 41, 50, 75 Another benefit of using 123 I is the possibility to use SPECT in combination with planar scintigraphy. SPECT might enhance the possibility to delineate tumors, especially in regions with high activity in surrounding tissues, preferentially in the anterior-posterior direction. 27 For these reasons, I and has to be synthesized shortly before administration and is not commercially available in all countries. 35, 41 Another drawback with 123 I is the increased uptake, which can be seen in normal adrenal gland tissue, which might obscure small lesions located there. 48, 75 The normal adrenal medulla is rarely visualized with 131 I-MIBG; if so, the signal intensity is usually very low. 32, 41, 49 It has been claimed that the same image quality as seen with diagnostic amounts of 123 I can only be obtained with therapeutic amounts of 131 I. 49 
Aspects on measurement techniques
In scintigraphy, the choice of detector collimator is very important to obtain a high contrast together with a reasonably high spatial resolution. The latter is especially important for SPECT. In general, scintigraphy of 131 I is performed with a HE collimator due to the high main photon energy (Tables 1 and 4) , while 123 I scintigraphy is performed either with a LE or with a medium-energy (ME) collimator. In a theoretical study, the effect of the choice of collimator was evaluated. 81 Both
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I and 123 I emit photons of higher energy than their main emission (Table 1) ; although the yield of these photons is low, they may cause a clear degradation of the image quality. These HE photons may cause an increased background signal mainly due to septal penetration in the collimator and Compton interaction in the detector. 81 With an ME collimator, HE background signal contamination from 123 I-MIBG is effectively decreased (eg, by reduced septal penetration), resulting in an increased signal contrast versus that from an LE collimator, but with a reduced spatial resolution. For quantitative studies using 123 I-MIBG, ME collimators might then be preferred. [81] [82] [83] By applying scatter correction on images acquired with LE collimators, the contrast can be enhanced. Using triple energy window scatter correction, computer simulations indicate that the contrast is better with a low-energy high-resolution collimator than with an ME collimator. 81 However, a phantom study showed that regardless of reconstruction method, scatter correction, and attenuation correction, ME collimators still gave more accurate signal-contrast values. 82 Even though the detection of 364 keV photons from 131 I is high, problems with septal penetration for an HE collimator also occur, causing a decrease in image quality. It has been reported from simulations that the contrast of 131 I-MIBG SPECT is only 70% of that of 123 I-MIBG SPECT.
81

Other imaging techniques CT
CT is widely used for localization of PC/PGL due to the high availability, low cost, and fast performance. With CT, PC tumors .0.5-1 cm can be detected. 62, 84, 85 Overall, a sensitivity of 86%-100% and a specificity of 50%-98% have been reported (Table 6 ). For intra-adrenal tumors (.3 cm), the sensitivity was high for unilateral adrenal tumors, while much lower values were obtained for bilateral tumors, as could be expected when little or no adrenal medullary tissue is present as reference. 60, 80, [84] [85] [86] [87] For the detection of only PC, a sensitivity of 94%-100% was reported, while for PGL or recurrent PC, the sensitivity was reduced to 57%-89%. For PGL or recurrent tumors .1 cm in diameter, a sensitivity of 77%-98% and a specificity of 29%-92% were reported. 33 The sensitivity for CT was lower in some studies, and the lowest specificity (50%) was reported for patients prior to surgery. In the past years, the CT technique has rapidly developed with multidetector techniques and more sensitive detectors. This will enable the possibility to detect smaller tumors than before. Still, however, the problem with discrimination between tumor and normal tissue remains. Contrast-enhanced CT may give higher sensitivity and specificity. 88 The use of contrast agents for CT has long been avoided due to induction of hypertensive crisis in patients with PC using high-osmolar (ionic) contrast agents, but a recent study has indicated that low-osmolar (nonionic) contrast agents may be used in patients with PC not treated with adrenergic blockade. 89 
MRI
MRI has been widely used for diagnosis and follow-up of PC, both with and without gadolinium enhancement, and chemical shift imaging has been used to differentiate from cortical adenomas. With MRI, a sensitivity of 83%-100% and a specificity of 50%-100% have been reported (Table 7) . For PC, the sensitivity was 96%-100%, while for PGL, recurrent PC, or malignant PC, the sensitivity was reduced to 85%-88%.
The standard MRI sequences used for PC/PGL localizations are T1-weighted and T2-weighted sequences. In T1-weighted images, the PC will appear as hypo or isointense, with signal intensity similar or lower than that 
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Diagnostic imaging of pheochromocytoma of the liver and kidneys. However, the signal intensity will be enhanced in the presence of hemorrhage/hematoma or malignancy. 36, 90 In T2-weighted images, PC will appear hyperintense with up to 3 times the signal of the liver. 44, 85, 86 However, the hyperintense signal from PC in T2-weighted images is not specific; edematous and necrotic adrenocortical metastases also show this behavior. 44 In one study, T2-weighted MRI was found to be the most sensitive compared with 131 I-MIBG and/or CT. 86 Nevertheless, both T1-weighted and T2-weighted sequences are routinely used. The reason is that although T2-weighted images also make lesion characterization possible, T1-weighted images are necessary to detect tumors that cannot be distinguished from the adjacent fat on T2-weighted images. 85 Another possibility with MRI is diffusion-weighted imaging (DWI). PC/PGL has high signal intensity in DWI due to increased cellularity, resulting in restriction of the diffusion of water molecules. DWI has been shown to offer advantages in imaging metastases, especially lymph node and liver metastases. However, the specificity of DWI is poor and the depiction of normal lymph nodes and other normal structures is very common. It is, therefore, recommended that DWI should be used together with ordinary T1-weighted and T2-weighted imaging. 79 MRI has the advantage that imaging is less disturbed by distorted anatomy after surgery compared to CT, which is important when examining recurrent PC/PGL. 86 MRI is better than CT in detecting PGL, although the spatial resolution of MRI has been somewhat lower than that of CT. 44, 86, 91 MRI has a superior tissue contrast when compared to CT, which makes the use of paramagnetic contrast agents less necessary. There is a risk with contrast agents for inducing allergic reactions. In patients with PC, contrast agents can also induce a hypertensive crisis, which can be life-threatening. 84, 86, 91 Otherwise, the use of contrast agents in MRI may have some advantages. It gives the possibility to analyze the vascularity of the lesions and also to differentiate between solid and cystic masses. 44 MRI does not use ionizing radiation, which makes it highly suited for imaging of pregnant women and children. 44, 69, 86 Comparison between MIBG, CT, and MRI There exists some controversy about which imaging technique (CT, MRI, and MIBG scintigraphy) should be used as standard and which should only be used in special cases. The controversy is understandable because of the many advantages and disadvantages that exist for each of the image modalities.
One advantage with MIBG scintigraphy is that it allows for identification of the lesion and also supplies both anatomic and functional information. 84, 92 It also has a low rate of both 
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Forssell-Aronsson et al false-positive and false-negative results. 41 The possibility of whole-body imaging with a single administration of MIBG makes it very cost-effective 41, 85, 91 and especially well suited to localize PGL and recurrent PC as well as malignant PC/PGL. 44, 48, 58, 85, 92 Disadvantages with MIBG scintigraphy are lower spatial resolution, poor visualization of anatomical details, and poor 3-dimensional localization. 76, 91 In this respect, both CT and MRI are superior to MIBG scintigraphy. Today, the introduction of hybrid techniques, for example SPECT/CT, has reduced the last drawback mentioned above.
In patients, prior to adrenal surgery, the use of CT or MRI as the initial imaging technique is justified. PC is often benign and located in the adrenals for which both CT and MRI have a high sensitivity of detection. 54, 77, 78, 87, 93, 94 MIBG can be used in conjunction with CT and MRI to confirm a CA-handling tumor.
On the other hand, the use of MIBG scintigraphy as the initial imaging technique has also been discussed. With its whole-body screening potential, it can rule out extra-adrenal disease and act as a guide to subsequent CT and MRI investigations. This procedure can considerably raise the sensitivity of CT and MRI examination in the detection of PC. 54, 60, 69, 91 Tumors detected after surgery can be de novo tumors in hereditary disease or recurrences of a malignant PC/PGL. In a study comparing the sensitivity for detection of PC/PGL in patients prior to and after adrenal surgery, the proportion of patients with malignant disease was much higher after surgical treatment, indicating a higher sensitivity for recurrent disease (malignant PC/PGL) with MIBG. 77 When they compared the data with CT and MRI, opposite results were obtained. The sensitivity for CT or MRI was reduced by more than 20%, indicating a diminished detectability for malignant disease, while the specificity was increased in these patients. The results from these studies indicate that MIBG is also most useful in the detection of extra-adrenal tumors and metastases and tumors in patients with recurrent disease. 33, 48, 77, 91 However, there are arguments against the routine use of MIBG. Three studies challenge the use of MIBG to any larger extent. In all studies, MIBG revealed no extra information about the extent of the disease and in no cases did MIBG alter the management of the disease. They all state that in low-risk patients with sporadic unilateral PC, it is not economically acceptable to perform MIBG scintigraphy, but they agree that MIBG can be helpful in cases with recurrence and extra-adrenal lesions. 93, 95, 96 Some of the drawbacks with planar scintigraphy with 123 I-MIBG are effectively reduced using 123 I-MIBG SPECT.
SPECT is more sensitive than planar imaging, but the difference is small. The main difference between the two lies in the certainty of detection. The certainty with which lesions are detected is significantly enhanced, and SPECT makes it easier to evaluate adrenals with low uptake. This contributes to a more definitive diagnosis. Another advantage of SPECT is that the 3-dimensional location of the lesion can be determined. 71, 97 Other scintigraphic techniques Somatostatin receptor scintigraphy
Another scintigraphic method of detecting PC/PGL is by somatostatin receptor scintigraphy (SRS) with the radiolabeled somatostatin analog octreotide, usually Figure 1A) . The requirement for successful imaging is a reasonably high expression of somatostatin receptors (SSTRs), especially of subtype 2 and 5 by the tumor cells. Our own pilot studies on the quantitative SSTR mRNA expression using reverse transcriptase-polymerase chain reaction have shown relatively low levels of SSTR1 and SSTR2 in PC/PG versus very high levels in midgut carcinoids (,300 vs 9000 per 1000 β-actin copies). The tumor/blood activity concentration ratios in vivo for radiolabeled somatostatin analogs for PC/PG were limited to values around 40 (in two patients), but more tumor biopsy data are required before any firm conclusion on the uptake can be made. 37 Although the sensitivity for detection of benign PC has been shown to be low, 75 SRS can have a place in the evaluation for PC/PGL when malignancy is suspected. The reported detection efficiency of SRS varies. In some studies, 131 I/ 123 I-MIBG was shown superior to SRS, 98, 99 while in other studies, the opposite relationship was found.
75,100
However, SRS might be valuable for detection of MIBGnegative metastases. 75, 98, 101, 102 One study demonstrated the accumulation of radiolabeled octreotide in sites not found with other imaging modalities, but several of these findings were probably false positive. 99 SRS is well suited to diagnose parasympathetic PGL. A reported sensitivity of 93% was found with SRS, while with 123 I-MIBG, the sensitivity was only 44%. Both the number of lesions detected and the intensity of uptake were superior with SRS compared with MIBG. 63, 103 
PET procedures
PET imaging is another way to depict PC/PGL. The general drawback of PET imaging is the short half-time of most of the used radionuclide, while the spatial resolution of PET is superior to that of scintigraphy. Recently, the use of PET/CT C-hydroxyephedrine ( 11 C-HED), and 11 C-epinephrine. The physical data on the radionuclides used for PET are given in Table 1. 124 I-MIBG has been proposed in planning for 131 I-MIBG radionuclide therapy and has been used in a pilot study on patients. 104 Labeling techniques to obtain high-specific activity has been developed. 105 The 124 I-MIBG imaging of xenografted cells expressing the human NET gene in animals has been successful, 106, 107 but to our knowledge, no clinical studies have yet been reported. 76 Br-MBBG has been produced and has similar pharmacokinetic behavior as MIBG. FDG is taken up by all tissues with high metabolic rate, including malignant tumors, and is thus a nonspecific method. [111] [112] [113] Despite the nonspecific nature of the uptake, it has been speculated that malignant PC/PGL might accumulate FDG faster and to a higher extent than benign PC/PGL. 111 The sensitivity to detect benign PC/PGL is poor, but the use of FDG PET in malignant PC/PGL has advantages. 111 High sensitivity has been reported; MIBG detects more lesions and has better detection of bone and lung metastases, while FDG PET has shown promising results in the detection of lymph node metastases. 79, 114 FDG PET seems especially promising in detecting PC/PGL that has failed to accumulate MIBG, and it has been found that the combination of the two modalities successfully detected all lesions. 111, 113 In addition, FDA has proven effective in the detection of malignant PC/PGL (Figure 2 ). FDA is a CA precursor that binds to the cell membrane NET. In two studies, FDA PET correctly demonstrated all patients with malignant disease. 112, 115 FDA PET may also have a role in the detection of benign PC. However, FDA also accumulates in the normal adrenal gland which, as with 123 I-MIBG, may obscure the detection of PC. 116 FDA was proven superior to 131 I-MIBG in both sensitivity and intensity of uptake and showed lesions not detected by either MIBG, CT, or MRI. 112 However, since FDA binds to cell membrane NET, aggressive malignant PC/PGL can lose their uptake capacity of FDA and then can give false-negative results. In such cases, FDG has been proven a superior method. 103, 117 DOPA is a precursor to DA, and one study reported that using 18 F-DOPA, all primary benign PGL tumors were successfully visualized in all patients who were examined. High uptake of 18 F-DOPA was shown in most lesions and 18 F-DOPA PET was found superior to 123 I-MIBG. Furthermore, no uptake in the normal adrenal gland was observed. 118 Another study demonstrated a higher uptake of 18 F-DOPA in benign than in malignant PC/PGL, which makes the use of 18 F-DOPA PET in malignant PC/PGL questionable. 119 18 F-DOPA PET can be used in conjunction with carbidopa. Carbidopa is a drug 'which decreases the decarboxylation and subsequent renal clearance of DOPA'. By the use of this drug, an enhanced uptake was seen in PC/PGL, which could potentially enhance the sensitivity. 119 11 C-HED, which is a synthetic CA, has been used successfully to locate PC/PGL. 120-122 11 C-HED is rapidly accumulated in PC/PGL and within 5 min, the lesions can be seen, with increased accumulation over time. The uptake of 11 C-HED is higher than that of MIBG (better image contrast), and 11 C-HED PET has a much higher sensitivity and specificity than 131 I-MIBG. In a comparative study on PC/PGL, both 123 I-MIBG SPECT/CT and 11 C-HED PET/CT gave a sensitivity and specificity of 100%, but PET/CT visualized more lesions. 65 Although SPECT suffers from lower spatial resolution compared with PET, it can still be used, as 11 C-HED PET has the drawback of high normal uptake in the liver, which may obscure lesions.
11 C can also be bound to EPI. In the first study, a high sensitivity was reported with rapid uptake of 11 C-EPI, and the method might be complementary to MIBG, especially when MIBG fails to accumulate. 123 EPI is avidly transported into the presynaptic nerve terminal via a type 1 uptake and is stored in secretory granules in a similar manner as NE. More studies are needed to clinically evaluate the usefulness of 11 C-EPI versus the other scintigraphic methods.
Comparison between scintigraphic methods
In a cohort of patients with nonmetastatic and metastatic PC/PGL, the imaging properties of 123 I-MIBG scintigraphy, FDA PET, and SRS were compared on a per-patient basis. 102 The overall sensitivity was 90% for FDA PET, 76% for MIBG scintigraphy, and 22% for SRS. On a per-region basis, the overall sensitivity was 75% for FDA PET, 63% for MIBG scintigraphy, and 64% for SRS. In patients with metastatic (Figure 2 ). The authors concluded that FDA PET should be used to diagnose PC/PGL if the technique is available, due to its high sensitivity. Otherwise, 123 I-MIBG scintigraphy (for nonmetastatic or adrenal PC) and SRS (for metastatic PC/PGL) are the first choices. 102 Although SRS seems to be of limited use for detection of benign solitary/adrenal PCs, 8, 102 SRS can reveal extra-adrenal or metastatic disease not visualized by MIBG. 99, 101, 102, 124 It has been suggested that MIBG scintigraphy probably gives a better overall detection rate compared with SRS for malignant PC. 101 However, the MIBG uptake is, in general, lower in malignant PC due to a reduced expression of NET by less well-differentiated cells, which might limit the sensitivity. It has also been suggested that tumors of low differentiation might have higher SSTR expression. 125 Patients with malignant PC might, therefore, have negative MIBG scintigraphy but positive SRS examination. 75, 101, 102 Patients with predominant SRS-positive lesions had rapidly progressive disease at clinical and biochemical follow-up, which implies that SRS may provide prognostic information. 102 Furthermore, in patients with positive SRS and negative-MIBG scintigraphy, therapy using radiolabeled somatostatin analogs, such as 177 Lu-octreotate, might be better suited than 131 I-MIBG. 4, 126 In a recent comparative study, Timmers et al addressed the optimal functional imaging modality ( I-MIBG scintigraphy) to localize PGL and if genotype influenced the imaging results. 5 Discrepant results in previous studies relate to heterogeneous patient series regarding location (adrenal or extra-adrenal, abdominal, thoracic, or head and neck tumors), malignancy, and hereditary tumor forms. Their results show that nonmetastatic tumors were equally well imaged by all four functional techniques (Table 8 ). Their study confirmed previous studies, where 123 I-MIBG had high sensitivity for primary tumors but low for metastases. It has even been claimed that the only indication for this technique in metastatic disease is uptake studies prior to 131 I-MIBG therapy. Of the techniques studied, MIBG and FDA utilize the NET and VMAT transporters, while tyrosine is internalized into the cell via the amino acid transporter to be converted to DOPA. FDG utilizes a glucose transporter (Figure 3) . 18 F-DOPA PET had a similar sensitivity profile as 123 I-MIBG with high detection rate for primary tumors but low for metastases ( Table 8 ). The best imaging results were obtained with FDG PET/CT (88%) and FDA PET/CT (78%) in nonmetastatic lesions with somewhat lower sensitivity for metastatic lesions (74% and 76%, respectively). It is somewhat surprising that a nonspecific method like FDG has equal results as a CA-specific method like FDA PET.
Previous studies on hereditary tumors showed that FDA PET was superior to diagnose both VHL-associated and MEN 2-associated tumors, while FDG PET had a high sensitivity to diagnose patients with SDHB-associated malignancy (Table 8) . 74 The poor performance of 131 I-MIBG in VHL tumors may be related to limited expression of NET in these patients. 127 In a subgroup analysis in the study by Timmers et al, both FDA PET and FDG PET had high sensitivity (82% and 83%, respectively) to detect metastatic SDHB tumors in comparison with the poor results using 18 F-DOPA (20%) and 123 I-MIBG (57%). 5 The reason for the discrepant results of the CA-specific molecules 18 F-DOPA and FDA, both utilizing the same amino acid transporter, 
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Diagnostic imaging of pheochromocytoma is obscure. It may be related to more rapid metabolism of DOPA or different affinity to the VMAT-transporter system and low retention in the secretory granules. FDG uptake is an indicator of high-metabolic rate, but in the tumors with the loss of SDHB activity and upregulation of hypoxia genes, there is a shift from oxidative phosphorylation to aerobic glycolysis (Warburg effect). 128 This switch to less effective energy metabolism may explain a higher glucose need by the tumor, that is, higher FDG uptake.
Conclusion and future prospects
Since the introduction of MIBG scintigraphy, no clear increase in sensitivity and specificity for PC/PGL can be found. Instead, there is a large variation in these values between studies, both for Today, very few clinical studies comparing different scintigraphic-imaging strategies, including choice of radiopharmaceuticals, image acquisition, processing, and evaluation, have been performed that clearly show the best technique. One major reason is probably that it concerns rare tumor types, and few patients can be recruited per time period at a single hospital. It would be of great interest to establish well-designed and well-controlled clinical multicenter studies to improve diagnostic routines for PC/PGL.
In the future, it is likely that PET substances like 18 F-DOPA and 18 F-DA will be good complements to MIBG and somatostatin analogs in scintigraphy. It has already been suggested that FDA PET should be the first-line alternative because of its high sensitivity. It is also possible that different imaging strategies should be used dependent on the genotype of the tumor. 
